New Zealand markets close in 4 hours 29 minutes

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9300-0.0700 (-3.50%)
At close: 04:00PM EDT
1.9500 +0.02 (+1.04%)
After hours: 04:27PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.8300 - 2.0300
52-week range0.9700 - 3.2100
Avg. volume73,936
Market cap11.009M
Beta (5Y monthly)0.57
PE ratio (TTM)N/A
EPS (TTM)-2.9200
Earnings date12 Aug 2024 - 16 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.00
  • GlobeNewswire

    Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

    Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceu

  • GlobeNewswire

    Plus Therapeutics Announces New Employment Inducement Grants

    AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on May 8, 2024, it granted option awards to Charles Huang, the Company’s new Director of Capital Markets and Investor Relations. The Company agreed to grant these equity awards to Mr. Huang to induce him to commence emp


    Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...

    Explore key financial shifts, strategic acquisitions, and clinical advancements as PSTV navigates its Q1 2024 landscape.